Imatinib sickle cell

Reading File

Searching PubMed

imatinib "sickle cell disease"

Searching the Web

imatinib sickle cell disease mechanism clinical trial 2024 2025

Reading Article

Finding Sources

I now have enough material for a thorough answer. The textbook library doesn't have a dedicated imatinib-in-SCD section, but the PubMed data is rich. Let me compile the full response.

Imatinib in Sickle Cell Disease

This is an active area of drug repurposing research. Imatinib (Gleevec/Glivec), a multi-target tyrosine kinase inhibitor (TKI) originally developed for CML, is being explored for SCD through at least three distinct molecular mechanisms.

Rationale: Why Imatinib?

1. c-Kit / Mast Cell Inhibition

Mast cells are prominent contributors to SCD-related pain and neuroinflammation. Imatinib potently inhibits c-Kit (CD117), the receptor driving mast cell survival and degranulation. By depleting mast cell activity, imatinib may dampen the neurogenic inflammation that triggers or amplifies vaso-occlusive crisis (VOC).

Mast cell activation has been shown to cause blood-brain barrier disruption in SCD through endothelial endoplasmic reticulum stress [PMID: 30837844].
The pilot clinical study (Karimi et al., 2024, PMID: 37652804) explicitly used imatinib at 100 mg twice daily as a mast cell inhibitor.

2. Syk Kinase Inhibition - Band 3 Pathway

Noomuna et al. (2020) proposed a key mechanism: in SCD, HbS denaturation releases heme and generates intracellular oxidants, which inhibit erythrocyte tyrosine phosphatases, causing constitutive phosphorylation of Band 3 (the major red cell membrane anion transporter). This leads to:

Dissociation of the spectrin-actin cytoskeleton from the membrane
Membrane weakening and discharge of microparticles (which activate coagulation)
Release of cell-free HbS (which scavenges nitric oxide)
Endothelial activation and upregulation of adhesion receptors

Imatinib inhibits Syk tyrosine kinase, which phosphorylates Band 3. In preclinical work, Syk inhibition blocked Band 3 phosphorylation, prevented free Hb release, reduced sickling adhesion to endothelium, and improved microcapillary flow. The authors specifically flagged imatinib as a repurposing candidate on this basis [PMID: 32346864].

3. PDGF-B / Fibrosis / Hypoxia-Reperfusion Pathway

The 2023 humanized mouse study (Federti et al., HemaSphere, PMID: 36874380) demonstrated that imatinib acts as a multimodal agent in SCD by:

Targeting signal transduction pathways in both hemolytic anemia and inflammatory vasculopathy
Inhibiting the PDGF-B-dependent profibrotic pathway activated by hypoxia/reperfusion injury (the model used to mimic acute VOCs)
Reducing end-organ injury markers in humanized SCD mice

This makes imatinib potentially useful not just for acute VOC prevention but also for reducing chronic organ damage (renal fibrosis, pulmonary hypertension, etc.).

Clinical Evidence

Study	Design	Key Findings
Stankovic Stojanovic et al., 2011 (PMID: 21488859)	Case report - patient with both CML and SCD on imatinib	Reduction in VOC frequency observed; first clinical signal
Karimi et al., 2024 (PMID: 37652804)	7 patients, HU-resistant, ≥4 VOC/year; imatinib 100 mg BID	Hospitalizations reduced 16-fold; chronic pain reduced >70%; opioid/NSAID demand fell in all patients; no significant change in hematological parameters
IMPACT SCA Trial (NCT listed, Indiana/Riley Children's)	Pilot study; imatinib for pain in chronic SCA	Ongoing/recently completed per available records

The Iranian pilot (Karimi 2024) is small (n=7) but striking - the magnitude of benefit in a hydroxyurea-refractory population is notable. Side effects were mild-moderate and reversible: edema, muscle cramps, nausea, rash, fatigue, GI symptoms (>10% incidence).

Mechanism Summary

HbS polymerization
      ↓
Oxidative stress → phosphatase inhibition
      ↓
Band 3 hyperphosphorylation (Syk-dependent)  ← IMATINIB blocks Syk
      ↓
Cytoskeletal dissociation, microparticles, free HbS, NO depletion
      ↓
Endothelial adhesion, vaso-occlusion

c-Kit on mast cells  ← IMATINIB blocks c-Kit
      ↓
Neuroinflammation, pain, BBB injury

PDGF-B pathway  ← IMATINIB blocks PDGFR-β
      ↓
Hypoxia/reperfusion fibrosis, chronic organ damage

Current Status & Limitations

No FDA/EMA approval for SCD; purely investigational
Evidence base is still preclinical + small case series - no phase 2/3 RCT results published yet
The IMPACT SCA pilot study is the most formal clinical trial identified
Dose used in the clinical pilot (100 mg BID) is lower than standard CML dosing (400 mg/day), suggesting a favorable safety margin may exist
Imatinib does not directly increase HbF (unlike hydroxyurea) or address the primary globin defect
Drug repurposing is appealing given imatinib's known safety profile from decades of CML use

Key References

Federti et al., HemaSphere 2023 - humanized mouse multimodal protection [PMID: 36874380]
Karimi et al., Hematol Transfus Cell Ther 2024 - pilot clinical data [PMID: 37652804]
Noomuna et al., Br J Haematol 2020 - Band 3 / Syk mechanism [PMID: 32346864]
Stankovic Stojanovic et al., Br J Haematol 2011 - first case report [PMID: 21488859]

The field is moving from "interesting case observation" toward mechanistic validation and early clinical trials. Larger controlled trials are needed before imatinib can be considered a standard adjunct in SCD management.

This is a shared conversation. Sign in to Orris to start your own chat.